Accretion Pharmaceuticals IPO Subscription Status
Accretion Pharmaceuticals IPO received bids for 2,00,06,400 shares against 25,87,300 offered, an overall subscription of 7.73x at the close of bidding (16 May 2025). QIBs lead at 12.14x.
Last updated · day 3 figures
- Retail
- 10.55x
- NII
- 4.41x
- QIB
- 12.14x
- Total
- 7.73x
Where the demand is
Accretion Pharmaceuticals IPO subscription by category
| Category | Shares offered | Shares bid | Amount bid | Subscription |
|---|---|---|---|---|
| QIB | 1,41,700 | 17,19,600 | ₹17.37 Cr | 12.14x |
| NII | 12,22,800 | 53,91,600 | ₹54.46 Cr | 4.41x |
| Retail | 12,22,800 | 1,28,95,200 | ₹130.24 Cr | 10.55x |
| Total | 25,87,300 | 2,00,06,400 | ₹202.06 Cr | 7.73x |
* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.
Accretion Pharmaceuticals IPO subscription day-wise
| Category | Day 3 |
|---|---|
| QIB | 12.14x |
| NII | 4.41x |
| Retail | 10.55x |
| Total | 7.73x |
| Total added | 7.73x |
Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.
Accretion Pharmaceuticals IPO reservation
| Category | Shares | Share of issue |
|---|---|---|
| Qualified Institutional Buyers | 1,41,700 | 5.48% |
| Non-Institutional Investors | 12,22,800 | 47.26% |
| Retail Individual Investors | 12,22,800 | 47.26% |
| Public issue | 25,87,300 | 100% |
Allotment Chances Note
These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:
- Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
- Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
- Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.
Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.
Accretion Pharmaceuticals IPO subscription: FAQs
- What is the overall subscription of Accretion Pharmaceuticals IPO?
- Accretion Pharmaceuticals IPO is subscribed 7.73x overall as of day 3 (16 May 2025), with bids for 2,00,06,400 shares against 25,87,300 offered.
- What is the retail subscription of Accretion Pharmaceuticals IPO?
- The retail portion is subscribed 10.55x as of day 3 (16 May 2025).
- What is the QIB and NII subscription of Accretion Pharmaceuticals IPO?
- QIBs have subscribed 12.14x of their portion, and NIIs 4.41x as of day 3 (16 May 2025).
- How can I check Accretion Pharmaceuticals IPO subscription status live?
- This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
- How do I apply for Accretion Pharmaceuticals IPO?
- Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 16 May 2025.
Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.